Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Fernandezsean72on Apr 26, 2022 12:45pm
143 Views
Post# 34632566

RE:RE:HOW MANY TIMES WILL WE RS?

RE:RE:HOW MANY TIMES WILL WE RS?
Claritas Facebook

Just seeing if anybody is interested in taking part in a convertible debenture.  
 
The way it works is say you own a hundred thousand shares worth 13 cents ($13,000)
 
You sell your shares and take the cash to buy into the debenture.  Once you do the company will provide you with either a principal interest on your $13,000 of say 15% ($1,950) or a discount on the shares you will receive at the end (6 months)
 
Depending on how it is agreed on (as it can go a few ways but here is a typical agreement) you have loaned the company $13,000 and immediately received $1,900 tacked onto your total owed to you ($14,950) which will be paid out in 6 months to you.
 
At the end of six months, if you do not wish to take the cash and instead with to convert, the conversion rate will be somewhere around todays share price of 13 cents with each share being accompanied by a warrant good for two years with an exercise price of slightly above todays share price (14 – 18 cents)
 
So, on conversion one can expect to receive 115,000 shares and 115,000 warrants at or around todays share price of 13 cents even if the going share price at time of conversion is $1 -$10.
 
If the share price goes down, you take the money and earn the interest.  If the share price goes up, you are making money.  In all, it is less riskier than owning the shares which can fluctuate down or up as you have locked in a pretty low price in a stock which should move upwards fairly high rather quickly.
<< Previous
Bullboard Posts
Next >>